Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
IVVD vs ADMA vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Beverages - Non-Alcoholic
IVVD vs ADMA vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Beverages - Non-Alcoholic |
| Market Cap | $102M | $1.90B | $355.61B |
| Revenue (TTM) | $56M | $510M | $49.28B |
| Net Income (TTM) | $-78M | $165M | $13.70B |
| Gross Margin | 92.0% | 61.3% | 61.7% |
| Operating Margin | -146.4% | 42.1% | 29.3% |
| Forward P/E | — | 9.9x | 25.3x |
| Total Debt | $2M | $80M | $45.49B |
| Cash & Equiv. | $227M | $88M | $10.27B |
IVVD vs ADMA vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 21 | Jun 26 | Return |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 100 | 2.3 | -97.7% |
| ADMA Biologics, Inc. (ADMA) | 100 | 612.7 | +512.7% |
| The Coca-Cola Compa… (KO) | 100 | 146.7 | +46.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IVVD vs ADMA vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
IVVD is the clearest fit if your priority is growth exposure.
- Rev growth 110.5%, EPS growth 79.0%
- 110.5% revenue growth vs KO's 1.9%
ADMA carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.11
- Lower volatility, beta 1.11, Low D/E 16.7%, current ratio 6.71x
- Beta 1.11, current ratio 6.71x
KO is the clearest fit if your priority is long-term compounding.
- 121.1% 10Y total return vs ADMA's 15.3%
- 2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend
- +17.2% vs ADMA's -62.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 110.5% revenue growth vs KO's 1.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 32.4% margin vs IVVD's -138.9% | |
| Stability / Safety | Beta 1.11 vs IVVD's 2.03 | |
| Dividends | 2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +17.2% vs ADMA's -62.0% | |
| Efficiency (ROA) | 27.4% ROA vs IVVD's -41.6%, ROIC 36.0% vs -494.9% |
IVVD vs ADMA vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IVVD vs ADMA vs KO — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ADMA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 882.2x IVVD's $56M. ADMA is the more profitable business, keeping 32.4% of every revenue dollar as net income compared to IVVD's -138.9%. On growth, IVVD holds the edge at +21.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $56M | $510M | $49.3B |
| EBITDAEarnings before interest/tax | -$80M | $221M | $15.5B |
| Net IncomeAfter-tax profit | -$78M | $165M | $13.7B |
| Free Cash FlowCash after capex | -$79M | $108M | $12.6B |
| Gross MarginGross profit ÷ Revenue | +92.0% | +61.3% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -146.4% | +42.1% | +29.3% |
| Net MarginNet income ÷ Revenue | -138.9% | +32.4% | +27.8% |
| FCF MarginFCF ÷ Revenue | -142.2% | +21.2% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.6% | -0.3% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.1% | +72.7% | +18.2% |
Valuation Metrics
IVVD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 13.7x trailing earnings, ADMA trades at a 50% valuation discount to KO's 27.2x P/E. On an enterprise value basis, ADMA's 9.5x EV/EBITDA is more attractive than KO's 26.4x.
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $102M | $1.9B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | -$122M | $1.9B | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.57x | 13.68x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.92x | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | 9.50x | 26.39x |
| Price / SalesMarket cap ÷ Revenue | 1.91x | 3.73x | 7.42x |
| Price / BookPrice ÷ Book value/share | 0.55x | 4.21x | 10.40x |
| Price / FCFMarket cap ÷ FCF | — | 68.40x | 67.15x |
Profitability & Efficiency
ADMA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-53 for IVVD. IVVD carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs IVVD's 3/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -53.5% | +39.0% | +41.1% |
| ROA (TTM)Return on assets | -41.6% | +27.4% | +13.1% |
| ROICReturn on invested capital | -4.9% | +36.0% | +15.8% |
| ROCEReturn on capital employed | -35.8% | +38.8% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 0.17x | 1.33x |
| Net DebtTotal debt minus cash | -$224M | -$8M | $35.2B |
| Cash & Equiv.Liquid assets | $227M | $88M | $10.3B |
| Total DebtShort + long-term debt | $2M | $80M | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 50.85x | 10.70x |
Total Returns (Dividends Reinvested)
Evenly matched — ADMA and KO each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADMA five years ago would be worth $44,620 today (with dividends reinvested), compared to $369 for IVVD. Over the past 12 months, KO leads with a +17.2% total return vs ADMA's -62.0%. The 3-year compound annual growth rate (CAGR) favors ADMA at 28.5% vs IVVD's -16.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -69.2% | -54.1% | +20.3% |
| 1-Year ReturnPast 12 months | -9.1% | -62.0% | +17.2% |
| 3-Year ReturnCumulative with dividends | -40.8% | +112.1% | +47.0% |
| 5-Year ReturnCumulative with dividends | -96.3% | +346.2% | +65.6% |
| 10-Year ReturnCumulative with dividends | -96.3% | +15.3% | +121.1% |
| CAGR (3Y)Annualised 3-year return | -16.0% | +28.5% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than IVVD's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs IVVD's 25.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 1.11x | -0.20x |
| 52-Week HighHighest price in past year | $3.07 | $22.20 | $84.04 |
| 52-Week LowLowest price in past year | $0.48 | $7.21 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +25.1% | +37.0% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 26.0 | 44.9 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 3.2M | 5.0M | 12.7M |
Analyst Outlook
KO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: IVVD as "Buy", ADMA as "Buy", KO as "Buy". Consensus price targets imply 1133.8% upside for IVVD (target: $10) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $9.50 | $21.00 | $86.13 |
| # AnalystsCovering analysts | 7 | 10 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 1 | 56 |
| Dividend / ShareAnnual DPS | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | +0.2% |
ADMA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Risk & Volatility, Analyst Outlook). 1 tied.
IVVD vs ADMA vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IVVD or ADMA or KO a better buy right now?
For growth investors, Invivyd, Inc.
(IVVD) is the stronger pick with 110. 5% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Invivyd, Inc. (IVVD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IVVD or ADMA or KO?
On trailing P/E, ADMA Biologics, Inc.
(ADMA) is the cheapest at 13. 7x versus The Coca-Cola Company at 27. 2x. On forward P/E, ADMA Biologics, Inc. is actually cheaper at 9. 9x.
03Which is the better long-term investment — IVVD or ADMA or KO?
Over the past 5 years, ADMA Biologics, Inc.
(ADMA) delivered a total return of +346. 2%, compared to -96. 3% for Invivyd, Inc. (IVVD). Over 10 years, the gap is even starker: KO returned +121. 1% versus IVVD's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IVVD or ADMA or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Invivyd, Inc. 's 2. 03β — meaning IVVD is approximately -1115% more volatile than KO relative to the S&P 500. On balance sheet safety, Invivyd, Inc. (IVVD) carries a lower debt/equity ratio of 1% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — IVVD or ADMA or KO?
By revenue growth (latest reported year), Invivyd, Inc.
(IVVD) is pulling ahead at 110. 5% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Invivyd, Inc. grew EPS 79. 0% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IVVD or ADMA or KO?
ADMA Biologics, Inc.
(ADMA) is the more profitable company, earning 28. 8% net margin versus -98. 2% for Invivyd, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -104. 0% for IVVD. At the gross margin level — before operating expenses — IVVD leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IVVD or ADMA or KO more undervalued right now?
On forward earnings alone, ADMA Biologics, Inc.
(ADMA) trades at 9. 9x forward P/E versus 25. 3x for The Coca-Cola Company — 15. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IVVD: 1133. 8% to $9. 50.
08Which pays a better dividend — IVVD or ADMA or KO?
In this comparison, KO (2.
5% yield) pays a dividend. IVVD, ADMA do not pay a meaningful dividend and should not be held primarily for income.
09Is IVVD or ADMA or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Invivyd, Inc. (IVVD) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, IVVD: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IVVD and ADMA and KO?
These companies operate in different sectors (IVVD (Healthcare) and ADMA (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: IVVD is a small-cap high-growth stock; ADMA is a small-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while IVVD, ADMA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.